Publication Details

Category Text Publication
Reference Category Book chapters
DOI 10.1007/978-3-662-04183-3_10
Title (Primary) The hybrid cell vaccination approach to cancer immunotherapy
Title (Secondary) Therapeutic vaccination strategies
Author Trefzer, U.; Herberth, G. ORCID logo ; Sterry, W.; Walden, P.
Publisher Walden, P.; Sterry, W.; Hennekes, H.
Source Titel Ernst Schering Research Foundation Workshop
Year 2000
Department IMMU
Volume 30
Page From 155
Page To 166
Language englisch
Abstract A variety of cancer immunotherapy approaches aim at the induction of cytolytic T lymphocytes (CTLs) as main effector cells in anti-tumor immune responses. However, the mere existence of the tumor proves the failure of immune surveillance and points at immune response defects. Antigenicity is prerequisite for specific immunotherapy and has been proven or is suggested by indirect evidence for several tumors. The failure of the immune system to cope with the cancer in these cases must therefore be attributed to immune regulatory problems including immune suppression, the lack of costimulatory support, or, very importantly, the lack of T cell help for the induction of cytolytic T effector cells. In addition, to become instrumental for clinical application, immunotherapy protocols must be suitable for highly individualized treatments and applicable without lengthy preparations.
Persistent UFZ Identifier https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=11157
Trefzer, U., Herberth, G., Sterry, W., Walden, P. (2000):
The hybrid cell vaccination approach to cancer immunotherapy
In: Walden, P., Sterry, W., Hennekes, H. (eds.)
Therapeutic vaccination strategies
Ernst Schering Research Foundation Workshop 30
Springer, Berlin, Heidelberg, p. 155 - 166 10.1007/978-3-662-04183-3_10